Obagi Chase Ends As Investors Approve $414M Valeant Bid
Valeant Pharmaceuticals International Inc. on Thursday officially ended its monthlong pursuit of California cosmetics company Obagi Medical Products Inc., winning approval from a majority of the company's investors for a $414...To view the full article, register now.
Already a subscriber? Click here to view full article